{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:38:43Z","timestamp":1786372723573,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,10]]},"abstract":"\n Background and objectives<\/jats:title>\n RRT and doubling of serum creatinine are considered the objective hard end points in nephrology intervention trials. Because both are assumed to reflect changes in the filtration capacity of the kidney, drug effects, if present, are attributed to kidney protection. However, decisions to start RRT are not only on the basis of filtration capacity of the kidney, but also on other factors. We therefore compared the time to RRT with the time to a fixed eGFR threshold and assessed the effect of the renoprotective drug irbesartan on both components.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n \n Post hoc<\/jats:italic>\n analysis of two clinical trials, the Irbesartan Diabetic Nephropathy Trial (IDNT) and Reduction of End points in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial, in patients with type 2 diabetes and nephropathy. The time to a predefined eGFR level of 11 ml\/min per 1.73 m\n 2<\/jats:sup>\n (eGFR\n 11<\/jats:sub>\n ), calculated by within-patient linear regression, was compared with the time to RRT or sustained serum creatinine \u22656 mg\/dl.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A large difference was observed in the median time to RRT (779 days) compared with eGFR\n 11<\/jats:sub>\n (678 days;\n P<\/jats:italic>\n =0.01). We also observed a large variation in the difference between the time to RRT and eGFR\n 11<\/jats:sub>\n . In IDNT, the hazard ratio for the effect of irbesartan on the serum creatinine \u22656.0 mg\/dl end point was 0.60 (95% confidence interval, 0.39 to 0.91;\n P<\/jats:italic>\n =0.02), whereas it was smaller for the RRT end point (hazard ratio, 0.78; 95% confidence interval, 0.58 to 1.07;\n P<\/jats:italic>\n =0.12).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study shows a difference in the time to RRT and a fixed eGFR threshold, and shows that the effect of an angiotensin receptor blocker on a filtration-based end point versus RRT varies. This implies that evaluating renoprotective effects of drugs with a combined RRT and doubling of serum creatinine end point may result in evaluating other effects beyond renoprotection alone. Future trials should consider registering all parameters that lead to RRT decisions.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.09590916","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T21:00:26Z","timestamp":1505768426000},"page":"1595-1600","source":"Crossref","is-referenced-by-count":7,"title":["Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?"],"prefix":"10.2215","volume":"12","author":[{"given":"Misghina","family":"Weldegiorgis","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie P.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Vanderbilt Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mol","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"c195","DOI":"10.1159\/000327614","article-title":"Is doubling of serum creatinine a valid clinical \u2018hard\u2019 endpoint in clinical nephrology trials?","volume":"119","author":"Lambers Heerspink","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3317\/jraas.2000.062","article-title":"The losartan renal protection study--Rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).","volume":"1","author":"Brenner","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/ndt\/15.4.487","article-title":"The Irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics.","volume":"15","author":"Rodby","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"Suppl","key":"B9-20230813","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","year":"2013","journal-title":"Kidney Int"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1053\/j.ajkd.2011.12.009","article-title":"Longitudinal progression trajectory of GFR among patients with CKD.","volume":"59","author":"Li","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/ndt\/gfp264","article-title":"Residual renal function at the start of dialysis and clinical outcomes.","volume":"24","author":"Stel","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.ajkd.2012.07.015","article-title":"Factors influencing the decision to start renal replacement therapy: Results of a survey among European nephrologists.","volume":"60","author":"van de Luijtgaarden","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"E277","DOI":"10.1503\/cmaj.111355","article-title":"Factors influencing patient choice of dialysis versus conservative care to treat end-stage kidney disease.","volume":"184","author":"Morton","year":"2012","journal-title":"CMAJ"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/ndt\/gfu257","article-title":"COnsiderations of Nephrologists when SuggestIng Dialysis in Elderly patients with Renal failure (CONSIDER): A discrete choice experiment.","volume":"29","author":"Foote","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/ndt\/15.10.1647","article-title":"Stewardship or clinical freedom? variations in dialysis decision making.","volume":"15","author":"Kee","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1681\/ASN.2014010042","article-title":"Randomized placebo-controlled EPPIC trials of AST-120 in CKD.","volume":"26","author":"Schulman","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1681\/ASN.V271186","article-title":"Spontaneous changes in the rate of decline in reciprocal serum creatinine: Errors in predicting the progression of renal disease from extrapolation of the slope.","volume":"2","author":"Shah","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ki.2013.47","article-title":"The GFR and GFR decline cannot be accurately estimated in type 2 diabetics.","volume":"84","author":"Gaspari","year":"2013","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201710000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:15Z","timestamp":1786369035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201710000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.09590916","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,18]]}}}